U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12B-25
NOTIFICATION
OF LATE FILING
| |
SEC
FILE NUMBER
333-258528 |
| |
|
| |
CUSIP
NUMBER
76133Y105 |
| (Check One): |
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K |
| |
|
☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form
N-CSR |
For
Period Ended: March 31, 2026
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
For
the Transition Period Ended: N/A
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A
| PART
I. |
REGISTRANT
INFORMATION. |
Retinalgenix
Technologies, Inc.
Full
Name of Registrant
Former
Name if Applicable
409
Apollo Beach Blvd. Suite 6
Address
of Principal Executive Office (Street and Number)
Apollo
Beach, Florida 33572
City,
State and Zip Code
| PART
II. |
RULES
12B-25 (b) AND (c) |
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
☒ |
(a) |
The
reasons described in reasonable detail in Part III of this Form could not be eliminated without
unreasonable effort or expense;
|
| |
|
| (b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K,
Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report or transition report
on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date; and
|
| |
|
| (c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached
if applicable.
|
The
Company is unable to file its Quarterly Report on Form 10Q ended March 31, 2026 by May 15, 2026 without unreasonable effort
or expense. The Company requires additional time to finalize its financial statements for such quarterly period.
| PART
IV. |
OTHER
INFORMATION |
| |
(1) |
Name
and telephone number of person to contact in regard to this notification: |
| |
Jerry Katzman |
(415) 578-9583 |
| |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the Company was required to file such report(s)
been filed? If the answer is no, identify report(s). |
| |
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings to be included in the subject report or portion thereof? |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Retinalgenix
Technologies, Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
| |
RETINALGENIX
TECHNOLOGIES, INC. |
| |
|
|
| Dated:
May 15, 2026 |
By: |
/s/
Jerry Katzman |
| |
|
Jerry
Katzman |
| |
|
Chief
Executive Officer |
